(Q33488076)

27 July 2017

1 reference

title

Tinzaparin. A review of its pharmacology and clinical potential in the prevention and treatment of thromboembolic disorders (English)

1 reference

27 July 2017

1 reference

H A Friedel

1

1 reference

27 July 2017

J A Balfour

series ordinal

2

1 reference

27 July 2017

language of work or name

1 reference

1 October 1994

1 reference

27 July 2017

1 reference

27 July 2017

volume

48

1 reference

27 July 2017

issue

4

1 reference

27 July 2017

page(s)

638-660

1 reference

Neutralization of a low molecular weight heparin (LHN-1) and conventional heparin by protamine sulfate in rats

27 July 2017

cites work

1 reference

12 December 2020

Neutralisation of heparan sulphate and low molecular weight heparin by protamine.

1 reference

12 December 2020

Inhibition of thrombin generation by heparin and low molecular weight (LMW) heparins in the absence and presence of platelet factor 4 (PF4)

1 reference

12 December 2020

Heparin pharmacokinetics and pharmacodynamics

1 reference

12 December 2020

Factor Xa inhibition: correlation between the plasma levels of anti-Xa activity and occurrence of thrombosis and haemorrhage

1 reference

12 December 2020

Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis

1 reference

12 December 2020

The diagnosis and treatment of deep-vein thrombosis

1 reference

12 December 2020

Inhibition of low molecular weight heparin by protamine chloride in vivo

1 reference

12 December 2020

Characterization of platelet binding of heparins and other glycosaminoglycans

1 reference

12 December 2020

The effect of low molecular weight heparin on experimental thrombosis and haemostasis--the influence of production method

1 reference

12 December 2020

Oligosaccharide mapping of low molecular weight heparins: structure and activity differences

1 reference

12 December 2020

Biologic tolerance of two different low molecular weight heparins

1 reference

12 December 2020

A comparison of the antithrombotic effects of heparin and of low molecular weight heparins with increasing antifactor Xa/antifactor IIa ratio in the rabbit

1 reference

12 December 2020

Prevention of thromboembolism after spinal cord injury

1 reference

12 December 2020

Influence of a low molecular weight heparin on the inhibition of factor Xa and thrombin in hip surgery

1 reference

12 December 2020

Low-molecular-weight heparins for the treatment of deep-vein thrombosis.

1 reference

12 December 2020

Pharmacokinetics of heparin and low molecular weight heparin

1 reference

12 December 2020

Prevention of perioperative deep vein thrombosis in general surgery: a multicentre double blind study comparing two doses of Logiparin and standard heparin. H.B.P.M. Research Group

1 reference

12 December 2020

A comparison of the antithrombotic and haemorrhagic effects of a low molecular weight heparin (LHN-1) and conventional heparin

1 reference

12 December 2020

Effect of tissue factor pathway inhibitor (TFPI) in the HEPTEST assay and in an amidolytic anti factor Xa assay for LMW heparin

1 reference

12 December 2020

Pharmacokinetics of a low molecular weight heparin, logiparin, after intravenous and subcutaneous administration to healthy volunteers

1 reference

12 December 2020

Dose adjusted heparin treatment of deep venous thrombosis: a comparison of unfractionated and low molecular weight heparin.

1 reference

12 December 2020

Low molecular weight heparin

1 reference

12 December 2020

Prevention of thromboembolism in 190 hip arthroplasties. Comparison of LMW heparin and placebo

1 reference

12 December 2020

Low molecular weight heparin Novo (LHN-1) does not cross the placenta during the second trimester of pregnancy

1 reference

12 December 2020

Synergism between full length TFPI and heparin: evidence for TFPI as an important factor for the antithrombotic activity of heparin

1 reference

12 December 2020

Prevention of thromboembolism in spinal cord injury: role of low molecular weight heparin

1 reference

12 December 2020

Subcutaneous treatment of deep venous thrombosis with low molecular weight heparin. A dose finding study with LMWH-Novo

1 reference

12 December 2020

Prevention of venous thrombosis and pulmonary embolism. NIH Consensus Development

1 reference

12 December 2020

The effect of heparin fragments of different molecular weights on experimental thrombosis and haemostasis.

1 reference

12 December 2020

Prevention of venous thromboembolism

1 reference

12 December 2020

Kinetics of intravenously administered heparin in normal humans

1 reference

12 December 2020

An approach to assigning in vitro potency to unfractionated and low molecular weight heparins based on the inhibition of prothrombin activation and catalysis of thrombin inhibition

1 reference

12 December 2020

Low-molecular-weight heparin.

1 reference

12 December 2020

Nadroparin calcium. A review of its pharmacology and clinical applications in the prevention and treatment of thromboembolic disorders

1 reference

12 December 2020

Effects of low molecular weight heparin and unfragmented heparin on induction of osteoporosis in rats

1 reference

12 December 2020

A comparison of subcutaneous low-molecular-weight heparin with warfarin sodium for prophylaxis against deep-vein thrombosis after hip or knee implantation

1 reference

12 December 2020

Levels of thrombin--antithrombin-III complex and factor VIII activity in relation to post-operative deep vein thrombosis and influence of prophylaxis with a low-molecular-weight heparin.

1 reference

12 December 2020

Monitoring therapy with LMW heparin: a comparison of three chromogenic substrate assays and the Heptest clotting assay.

1 reference

12 December 2020

Low-Mr heparin is as potent as conventional heparin in releasing lipoprotein lipase, but is less effective in preventing hepatic clearance of the enzyme

1 reference

12 December 2020

Prevention of thromboembolism after spinal cord injury using low-molecular-weight heparin

1 reference

12 December 2020

The present status of tissue factor pathway inhibitor

1 reference

12 December 2020

Interaction of size-fractionated heparins with lipoprotein lipase and hepatic lipase in the rat.

1 reference

12 December 2020

Biochemical and pharmacologic inequivalence of low molecular weight heparins

1 reference

12 December 2020

Plasma cross-linked fibrin degradation products fraction D in patients undergoing elective abdominal surgery

1 reference

12 December 2020

Comparative pharmacology of low molecular weight heparins: implications of manufacturing processes on biological effects

1 reference

12 December 2020

No transplacental passage of standard heparin or an enzymatically depolymerized low molecular weight heparin

1 reference

12 December 2020

Chemistry of heparin and low molecular weight heparin

1 reference

12 December 2020

Reduction of plasma levels of prothrombin fragments 1 and 2 during thromboprophylaxis with a low-molecular-weight heparin

1 reference

12 December 2020

Heparin/low molecular weight heparin and tissue factor pathway inhibitor

1 reference

12 December 2020

New aspects on heparin and lipoprotein metabolism

1 reference

12 December 2020

Effects of an enzymatically depolymerized heparin as compared with conventional heparin in healthy volunteers

1 reference

12 December 2020

Enoxaparin. A review of its pharmacology and clinical applications in the prevention and treatment of thromboembolic disorders

1 reference

12 December 2020

Low molecular weight heparin (Logiparin) as thromboprophylaxis in elective abdominal surgery. A dose finding study

1 reference

12 December 2020

Antithrombotic properties of a truncated recombinant tissue factor pathway inhibitor in an experimental venous thrombosis model

1 reference

12 December 2020

Low molecular weight heparin compared with dextran as prophylaxis against thrombosis after total hip replacement

1 reference

12 December 2020

Biological tolerance of Logiparin, a low molecular weight heparin used in patients undergoing total hip replacement

1 reference

12 December 2020

Relationship between pharmacokinetics and pharmacodynamics of tinzaparin (logiparin), a low molecular weight heparin, in dogs

1 reference

12 December 2020

Long-term use of low molecular weight heparin ameliorates hyperlipidemia in patients on hemodialysis

1 reference

12 December 2020

Validity of the newly established low-molecular-weight heparin standard in cross-referencing low-molecular-weight heparins

1 reference

12 December 2020

Involvement of the extrinsic pathway in the activities of low molecular weight heparins

1 reference

12 December 2020

Molecular and cellular biology of blood coagulation

1 reference

12 December 2020

Effect of heparin on the inhibition of the contact system enzymes

1 reference

12 December 2020

An international standard for low molecular weight heparin.

1 reference

12 December 2020

Association between plasma levels of tissue plasminogen activator and postoperative deep vein thrombosis--influence of prophylaxis with a low molecular weight heparin. The Venous Thrombosis Group

1 reference

12 December 2020

The extrinsic pathway inhibitor: a regulator of tissue factor-dependent blood coagulation

1 reference

12 December 2020

10.2165/00003495-199448040-00010

Identifiers

DOI

1 reference

Dimensions Publication ID

27 July 2017

1018157318

0 references

1 reference